Author: admin

DelveInsight’s “Knee Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Knee Osteoarthritis, historical and forecasted epidemiology as well as the Knee Osteoarthritis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Knee Osteoarthritis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Knee Osteoarthritis Market Forecast

Some of the key facts of the Knee Osteoarthritis Market Report:

• The Knee Osteoarthritis market size was valued ~USD 14, 400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.

• In September 2024, Cytonics announced the completion of patient enrollment in a Phase I clinical trial for CYT-108, which is being investigated as a potential disease-modifying therapy for knee osteoarthritis (OA). CYT-108 is a recombinant variant of the alpha-2-macroglobulin blood serum protease inhibitor.

• Among the 7MM, the US holds the largest market size for knee osteoarthritis (OA). This growth is driven by the emergence of new therapies, with the market size for knee OA estimated to be around USD 8,900 million in 2023.

• In May 2024, Organogenesis reported encouraging topline results from a Phase III randomized controlled trial assessing the safety and effectiveness of ReNu in managing symptoms of knee osteoarthritis.

• In 2023, the US recorded the highest number of prevalent cases, totaling approximately 18,499,200, followed by Japan.

• In the US, the age group of 70 years and older represented the highest number of cases in 2023, while the lowest number of cases was observed in the 18–39 age group.

• A study by Yokota et al. (2023) indicates that knee osteoarthritis is highly prevalent in Japan, affecting an estimated 25.3 million individuals over the age of 40, with around 8 million experiencing symptomatic cases.

• In 2023, there were approximately 97 million diagnosed cases of knee osteoarthritis in the 7MM. This number is expected to rise during the forecast period from 2024 to 2034.

• In 2023, within the EU4 and the UK, the highest proportion of age-specific knee osteoarthritis cases were observed in individuals aged 70 and above, followed by those in the 60-69 and 50-59 age groups.

• Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others

• Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others

• The Knee Osteoarthritis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Knee Osteoarthritis pipeline products will significantly revolutionize the Knee Osteoarthritis market dynamics.

Knee Osteoarthritis Overview

Knee osteoarthritis (OA) is a degenerative joint disease where the cartilage in the knee deteriorates over time, causing pain, stiffness, swelling, and reduced mobility. It is commonly associated with aging, injury, or overuse, leading to the wear and tear of the knee joint. Symptoms can range from mild discomfort to severe disability, often affecting daily activities.

Get a Free sample for the Knee Osteoarthritis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/knee-osteoarthritis-market

Knee Osteoarthritis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Knee Osteoarthritis Epidemiology Segmentation:

The Knee Osteoarthritis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Knee Osteoarthritis

• Prevalent Cases of Knee Osteoarthritis by severity

• Gender-specific Prevalence of Knee Osteoarthritis

• Diagnosed Cases of Episodic and Chronic Knee Osteoarthritis

Download the report to understand which factors are driving Knee Osteoarthritis epidemiology trends @ Knee Osteoarthritis Epidemiology Forecast

Knee Osteoarthritis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Knee Osteoarthritis market or expected to get launched during the study period. The analysis covers Knee Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Knee Osteoarthritis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Knee Osteoarthritis Therapies and Key Companies

• TLC599: Taiwan Liposome Company

• CNTX-4975: Centrexion Therapeutics

• Lorecivivint (SM04690): Biosplice Therapeutic

• HP-5000: Noven Pharmaceuticals

• Invossa (TG-C): Kolon TissueGene

• ZILOSUL (pentosan polysulfate sodium): Paradigm Biopharmaceuticals

• ReNu (Amniotic Suspension Allograft): Organogenesis

• JTA-004: BioSenic (Bone Therapeutics)

• Resiniferatoxin: Sorrento Therapeutics, Inc.

• ICM-203: ICM Biotech Australia

• RTX-GRT7039: Grünenthal GmbH

• StroMel: Akan Biosciences, LLC

• GSK3858279: GlaxoSmithKline

Discover more about therapies set to grab major Knee Osteoarthritis market share @ Knee Osteoarthritis Treatment Landscape

Knee Osteoarthritis Market Strengths

• New approaches to osteoarthritis therapy currently being investigated include attempts to identify disease-modifying osteoarthritis drugs, tissue engineering for reconstituting intact cartilage and joint tissues, and biomechanically active methods for reducing aberrant loading in osteoarthritis-involved joints.

• Single injection joint function enhancing hyaluronic acid formulation’s sales are steadily rising, and companies are looking to expand into new markets to increase their single injection product profit.

Knee Osteoarthritis Market Opportunities

• Disease-modifying osteoarthritis drugs (DMOADs) could offer new therapeutic targets to restore the quality and function of tissues affected by osteoarthritis.

• People eagerly await non-opioid options, and key players can target this lucrative market segment while others are developing therapies for the same.

Scope of the Knee Osteoarthritis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Knee Osteoarthritis Companies: Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutic, Noven Pharmaceuticals, Kolon TissueGene, Paradigm Biopharmaceuticals, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech Australia, Grünenthal GmbH, Akan Biosciences, LLC, GlaxoSmithKline, and others

• Key Knee Osteoarthritis Therapies: TLC599, CNTX-4975, Lorecivivint (SM04690), HP-5000, Invossa (TG-C), ZILOSUL (pentosan polysulfate sodium), ReNu (Amniotic Suspension Allograft), JTA-004, Resiniferatoxin, ICM-203, RTX-GRT7039, StroMel, GSK3858279, and others

• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies

• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Knee Osteoarthritis Unmet Needs, KOL’s views, Analyst’s views, Knee Osteoarthritis Market Access and Reimbursement

To know more about Knee Osteoarthritis companies working in the treatment market, visit @ Knee Osteoarthritis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Knee Osteoarthritis Market Report Introduction

2. Executive Summary for Knee Osteoarthritis

3. SWOT analysis of Knee Osteoarthritis

4. Knee Osteoarthritis Patient Share (%) Overview at a Glance

5. Knee Osteoarthritis Market Overview at a Glance

6. Knee Osteoarthritis Disease Background and Overview

7. Knee Osteoarthritis Epidemiology and Patient Population

8. Country-Specific Patient Population of Knee Osteoarthritis

9. Knee Osteoarthritis Current Treatment and Medical Practices

10. Knee Osteoarthritis Unmet Needs

11. Knee Osteoarthritis Emerging Therapies

12. Knee Osteoarthritis Market Outlook

13. Country-Wise Knee Osteoarthritis Market Analysis (2020–2034)

14. Knee Osteoarthritis Market Access and Reimbursement of Therapies

15. Knee Osteoarthritis Market Drivers

16. Knee Osteoarthritis Market Barriers

17. Knee Osteoarthritis Appendix

18. Knee Osteoarthritis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Knee Osteoarthritis Market to Expand Significantly by 2034, States DelveInsight Report | Paradigm Biopharma, Organogenesis, BioSenic (Bone Therapeutics), Sorrento Therapeutics, Inc., ICM Biotech

DelveInsight’s “Obesity Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Obesity market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obesity Market Forecast

Some of the key facts of the Obesity Market Report:

• The Obesity market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In January 2025, Viking Therapeutics initiated a Phase II clinical study for VK2735, an oral tablet developed to treat metabolic conditions like obesity. Named the VENTURE-Oral Dosing Trial, this randomized, double-blind, placebo-controlled, multi-center trial will evaluate the drug’s safety, tolerability, and effectiveness in promoting weight loss over a 13-week period.

• In January 2025, Novo Nordisk’s higher-dose formulation of Wegovy (semaglutide) proved effective in enhancing weight loss while maintaining safety and tolerability. In the Phase IIIb STEP UP trial, the 7.2 mg dose showed significantly greater weight reduction at week 72. A total of 1,407 obese adults were randomly assigned to receive weekly injections along with lifestyle modifications.

• In January 2025, Novo Nordisk announced topline results from its Phase Ib/IIa trial evaluating amycretin for the treatment of overweight or obese individuals. The study investigated the safety, pharmacokinetics, efficacy, proof-of-concept, and tolerability of this dual GLP-1 and amylin receptor agonist. Conducted over 36 weeks, the trial featured single and multiple ascending doses, along with a dose-response analysis, to test three different weekly subcutaneous maintenance dose levels.

• In December 2024, Resalis Therapeutics launched its first-in-human Phase 1 clinical trial for RES-010, a novel non-coding RNA-based therapy aimed at modifying the course of obesity. Preclinical findings show that RES-010 effectively reduces fat mass while preserving lean mass and boosting energy expenditure. By targeting fat in key areas like visceral and liver tissues, RES-010 may complement current treatments such as GLP-1 receptor agonists and promote sustainable, long-term weight loss. The Phase 1 study (EUCT No: 2024-514871-17-00) will assess the compound’s safety, tolerability, pharmacokinetics, pharmacodynamics, and early signs of efficacy in healthy, overweight, and moderately obese individuals.

• In November 2024, Altasciences was honored to have collaborated with Metsera, Inc.—a clinical-stage biopharma company advancing innovative therapies for obesity and metabolic disorders—by providing support for its nonclinical and early-phase clinical studies. This includes contributions to a recent Phase I/II trial of MET-097i, a fully biased, ultra-long-acting GLP-1 receptor agonist administered via injection.

• In July 2024, Roche announced promising topline results from its ongoing multi-part Phase I clinical trial of CT-996, an oral GLP-1 receptor agonist intended for the treatment of type 2 diabetes (T2D) and obesity. Known as the CT-996-201 trial, this comprehensive, multi-cohort, double-blind, randomized, placebo-controlled study includes both single and multiple ascending dose arms, with two arms already completed. The trial aims to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of CT-996 in overweight or obese adults, regardless of their T2D status.

• In 2023, the United States held the largest market share for obesity, exceeding USD 2,000 million. This surpassed the market sizes of obesity in comparison to the European Union Four (EU4) countries (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• In June 2024, Researchers at the Children’s Hospital of Philadelphia (CHOP) have uncovered the mechanisms by which a specific molecule regulates insulin sensitivity, which could lead to the identification of a new therapeutic target for obesity-related type 2 diabetes.

• In June 2024, Novo Nordisk and Eli Lilly led the obesity market in Q1 2024, with Novo Nordisk reporting $6.3 billion and Eli Lilly $2.3 billion in sales from their weight-loss medications.

• In June 2024, The US House Ways and Means Committee has put forward a plan for Medicare to include coverage for GLP-1 weight-loss medications such as Wegovy and Zepbound.

• In June 2024, Zealand Pharma has announced a share issuance aimed at raising DKK 7 billion ($1 billion) to further develop its obesity treatment candidates.

• In June 2024, Form Health secured $38 million in a Series B funding round to advance its science-driven obesity care programs and improve its telehealth platform.

• In 2023, the United States held the largest obesity market share, exceeding USD 2,000 million, surpassing the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• By the year 2034, it is expected that WEGOVY (Semaglutide) and ZEPBOUND (Tirzepatide) will attain significant market dominance across the seven major markets.

• In recent times, there has been an increasing emphasis on the creation of innovative treatments for obesity, which encompass drug combinations like SAXENDA (Liraglutide), XENICAL (Orlistat), WEGOVY (Semaglutide), QYSMIA (Phentermine-Topiramate), among others.

• DelveInsight’s estimates suggest that approximately 60% of the total prevalent cases of obesity among adults in the 7 major markets (7MM) were accounted for by the United States in 2023.

• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• The Obesity market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obesity pipeline products will significantly revolutionize the Obesity market dynamics.

Obesity Overview

Obesity is a medical condition characterized by excessive body fat accumulation, which can negatively impact health. It is typically measured using the Body Mass Index (BMI), with a BMI of 30 or higher indicating obesity. This condition increases the risk of various health issues, including heart disease, diabetes, hypertension, and certain cancers. Obesity can result from multiple factors, such as poor diet, lack of physical activity, genetics, and hormonal imbalances. Effective management includes lifestyle changes, medical treatments, and, in some cases, surgical interventions to improve overall health and reduce associated risks.

Get a Free sample for the Obesity Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market

Obesity Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Obesity Epidemiology Segmentation:

The Obesity market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Obesity

• Prevalent Cases of Obesity by severity

• Gender-specific Prevalence of Obesity

• Diagnosed Cases of Episodic and Chronic Obesity

Download the report to understand which factors are driving Obesity epidemiology trends @ Obesity Epidemiology Forecast

Obesity Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obesity market or expected to get launched during the study period. The analysis covers Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obesity Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obesity Therapies and Key Companies

• IMCIVREE (setmelanotide): Rhythm Pharmaceuticals

• ZEPBOUND (tirzepatide): Eli Lilly and Company

• Survodutide (BI 456906): Boehringer Ingelhium

• DD03: D&D Pharmatech

• AX-0601: ProQR Therapeutics

• NPM 139: Nano Precision Medical

• BK-1701: Bukwang Pharmaceutical

• CBW-520: Caliway Biopharmaceutics

• YH34160: Yuhan

• TERN-601: Terns Pharmaceuticals

• Thermostem: BioRestorative Therapies

• SCO-267: SCOHIA PHARMA

• CT-181: Click Therapeutics

• HM15136: Hanmi Pharmaceuticals

• NNC0480-0389: Novo Nordisk

• EMP-16: Empros Pharma

• CT-868: Carmot Therapeutics

• Tirzepatide: Eli Lilly and Company

• SemaglutideOral: Novo Nordisk

Discover more about therapies set to grab major Obesity market share @ Obesity Treatment Landscape

Obesity Market Drivers

• Rise in prevalence of Obesity, growing Research and Development Activities to develop novel therapies to treat obesity, changing lifestyle patterns are some of the important factors that are fueling the Obesity Market.

Obesity Market Barriers

• However, challenges associated with the discovery of anti-obesity drugs, economic burden associated with obesity and other factors are creating obstacles in the Obesity Market growth.

Scope of the Obesity Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Obesity Companies: Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others

• Key Obesity Therapies: IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others

• Obesity Therapeutic Assessment: Obesity current marketed and Obesity emerging therapies

• Obesity Market Dynamics: Obesity market drivers and Obesity market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Obesity Unmet Needs, KOL’s views, Analyst’s views, Obesity Market Access and Reimbursement

To know more about Obesity companies working in the treatment market, visit @ Obesity Clinical Trials and Therapeutic Assessment

Table of Contents

1. Obesity Market Report Introduction

2. Executive Summary for Obesity

3. SWOT analysis of Obesity

4. Obesity Patient Share (%) Overview at a Glance

5. Obesity Market Overview at a Glance

6. Obesity Disease Background and Overview

7. Obesity Epidemiology and Patient Population

8. Country-Specific Patient Population of Obesity

9. Obesity Current Treatment and Medical Practices

10. Obesity Unmet Needs

11. Obesity Emerging Therapies

12. Obesity Market Outlook

13. Country-Wise Obesity Market Analysis (2020–2034)

14. Obesity Market Access and Reimbursement of Therapies

15. Obesity Market Drivers

16. Obesity Market Barriers

17. Obesity Appendix

18. Obesity Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Market Set to Grow Substantially Through 2034, DelveInsight Projects | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical

The Steroid Refactory Acute Graft-Versus-Host Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Steroid Refactory Acute Graft-Versus-Host Disease market dynamics.

DelveInsight’s “Steroid Refactory Acute Graft-Versus-Host Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Steroid Refactory Acute Graft-Versus-Host Disease, historical and forecasted epidemiology as well as the Steroid Refactory Acute Graft-Versus-Host Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Steroid Refactory Acute Graft-Versus-Host Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Steroid Refactory Acute Graft-Versus-Host Disease Market Forecast

Some of the key facts of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:

• The Steroid Refactory Acute Graft-Versus-Host Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2025, MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech company specializing in Microbiome Ecosystem Therapies™ (MET) to improve cancer patient survival through immune modulation, announced that following the EMA Pediatric Committee’s approval of its Pediatric Investigation Plan (PIP), the Data and Safety Monitoring Board (DSMB) has completed its final safety review of the pivotal Phase 3 ARES trial. This single-arm, open-label, multicenter European study evaluates the efficacy and safety of MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) involving the gastrointestinal tract, who are receiving third-line treatment after being refractory to steroids and either refractory or intolerant to ruxolitinib.

• In December 2024, The FDA has approved remestemcel-L-rknd (Ryoncil) for treating pediatric patients aged two months and older with steroid-refractory acute graft-versus-host disease (GVHD), according to an agency announcement. The approval is supported by results from the multicenter, prospective, single-arm MSB-GVHD001 trial (NCT02336230), which evaluated the allogeneic bone marrow-derived MSC therapy in 54 children with steroid-refractory acute GVHD following allogeneic hematopoietic stem cell transplantation (HSCT).

• In December 2024, The FDA has granted approval to Mesoblast’s allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, remestemcel-L, for treating steroid-refractory acute graft-versus-host disease (GvHD) in children aged two months and older.

• The biopsy may help confirm Steroid Refactory Acute Graft-Versus-Host Disease diagnosis, but lacks sensitivity and specificity

• In around 35–50% of patients, aGVHD becomes refractory to systemic steroid therapy

• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others

• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others

• The Steroid Refactory Acute Graft-Versus-Host Disease diagnosis is carried through laboratory analysis, imaging, and or endoscopic

Steroid Refactory Acute Graft-Versus-Host Disease Overview

Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) is a serious and life-threatening complication that occurs after an allogeneic stem cell or bone marrow transplant. In this condition, the donated immune cells attack the recipient’s body tissues. Normally, steroids are the first line of treatment to control this immune response. However, in steroid-refractory cases, patients either do not respond to steroids or their symptoms worsen, making the disease harder to manage. SR-aGVHD often affects organs such as the skin, liver, and gastrointestinal tract and requires alternative therapies to improve survival and quality of life.

Request a sample for the Steroid Refactory Acute Graft-Versus-Host Disease Market Report:

https://www.delveinsight.com/report-store/steroid-refactory-acute-graft-versus-host-disease-gvhd-market

Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology Segmentation:

The Steroid Refactory Acute Graft-Versus-Host Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease

• Prevalent Cases of Steroid Refactory Acute Graft-Versus-Host Disease by severity

• Gender-specific Prevalence of Steroid Refactory Acute Graft-Versus-Host Disease

• Diagnosed Cases of Episodic and Chronic Steroid Refactory Acute Graft-Versus-Host Disease

Download the report to understand which factors are driving Steroid Refactory Acute Graft-Versus-Host Disease epidemiology trends @ Steroid Refactory Acute Graft-Versus-Host Disease Epidemiological Insights

Steroid Refactory Acute Graft-Versus-Host Disease Market

The dynamics of the Steroid Refactory Acute Graft-Versus-Host Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Itacitinib, MaaT013, and others during the forecasted period 2019-2032.

Steroid Refactory Acute Graft-Versus-Host Disease Therapies and Emerging Therapies

• MC0518: MaaT Pharma

• Neihulizumab: medac GmbH

• T-Guard: AltruBio Inc

• Ruxolitinib: Incyte Corporation

To know more about Steroid Refactory Acute Graft-Versus-Host Disease treatment, visit @ Steroid Refactory Acute Graft-Versus-Host Disease Medications

Steroid Refactory Acute Graft-Versus-Host Disease Market Drivers

• Rising Incidence of Hematopoietic Stem Cell Transplantation (HSCT)

• High Unmet Medical Need

• Regulatory Support & Designations

• Ongoing Clinical Trials & Emerging Therapies

• Increased Awareness & Diagnosis

Steroid Refactory Acute Graft-Versus-Host Disease Market Barriers

• Complex Pathophysiology

• High Cost of Treatment

• Limited Patient Pool

• Adverse Effects of Therapies

• Delayed Diagnosis and Referral

Scope of the Steroid Refactory Acute Graft-Versus-Host Disease Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Steroid Refactory Acute Graft-Versus-Host Disease Companies: MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation, and others

• Key Steroid Refactory Acute Graft-Versus-Host Disease Therapies: MC0518, Neihulizumab, T-Guard, Ruxolitinib, Apraglutide, and others

• Therapeutic Assessment: Steroid Refactory Acute Graft-Versus-Host Disease current marketed and Steroid Refactory Acute Graft-Versus-Host Disease emerging therapies

• Steriod Refactory Acute Graft-Versus Host Disease Market Dynamics: Steroid Refactory Acute Graft-Versus-Host Disease market drivers and barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Unmet Needs, KOL’s views, Analyst’s views, Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement

Discover more about therapies set to grab major Steroid Refactory Acute Graft-Versus-Host Disease market share @ Steroid Refactory Acute Graft-Versus-Host Disease Treatment Landscape

Table of Contents

1. Steroid Refactory Acute Graft-Versus-Host Disease Market Report Introduction

2. Executive Summary for Steroid Refactory Acute Graft-Versus-Host Disease

3. SWOT analysis of Steroid Refactory Acute Graft-Versus-Host Disease

4. Steroid Refactory Acute Graft-Versus-Host Disease Patient Share (%) Overview at a Glance

5. Steroid Refactory Acute Graft-Versus-Host Disease Market Overview at a Glance

6. Steroid Refactory Acute Graft-Versus-Host Disease Disease Background and Overview

7. Steroid Refactory Acute Graft-Versus-Host Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Steroid Refactory Acute Graft-Versus-Host Disease

9. Steroid Refactory Acute Graft-Versus-Host Disease Current Treatment and Medical Practices

10. Steroid Refactory Acute Graft-Versus-Host Disease Unmet Needs

11. Steroid Refactory Acute Graft-Versus-Host Disease Emerging Therapies

12. Steroid Refactory Acute Graft-Versus-Host Disease Market Outlook

13. Country-Wise Steroid Refactory Acute Graft-Versus-Host Disease Market Analysis (2019–2032)

14. Steroid Refactory Acute Graft-Versus-Host Disease Market Access and Reimbursement of Therapies

15. Steroid Refactory Acute Graft-Versus-Host Disease Market drivers

16. Steroid Refactory Acute Graft-Versus-Host Disease Market barriers

17. Steroid Refactory Acute Graft-Versus-Host Disease Appendix

18. Steroid Refactory Acute Graft-Versus-Host Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, medac GmbH, AltruBio Inc., Incyte Corporation

DelveInsight’s “Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast

Some of the key facts of the Myocardial Infarction Market Report:

• The Myocardial Infarction market size was valued approximately USD 21,750 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In August 2024, CellProthera announced a successful pre-investigational new drug (IND) meeting with the US Food and Drug Administration (FDA), bringing the company closer to launching a pivotal Phase III trial for its cell therapy targeting myocardial infarction. The France-based company stated that the FDA supported the trial design, which includes a two-year follow-up. The trial will assess the therapy’s effectiveness in preventing future heart diseases.

• In February 2024, Australian CSL announced the topline results from the Phase III AEGIS-II trial of CSL112 in patients after an acute myocardial infarction (MI). The results revealed that the drug did not achieve its primary endpoint of reducing the risk of major adverse cardiovascular events (MACE) within 90 days.

• Estimates suggest that the United States will hold the largest share of the Myocardial Infarction Market, with a value of approximately USD 16,300 million in 2023, driven by a higher number of cases and relatively higher treatment costs.

• In 2023, the total number of diagnosed prevalent cases of Myocardial Infarction across the 7MM was approximately 15.5 million, with expectations of growth during the forecast period.

• In 2023, the United States had approximately 8 million diagnosed prevalent cases of Myocardial Infarction.

• In 2023, the United States represented the largest share of the Myocardial Infarction prevalent population, accounting for approximately 55% of the 7MM. Meanwhile, EU4 and the UK contributed around 35%, and Japan made up about 10% of the total population share.

• DelveInsight estimates indicate that in 2023, the United States had approximately 3.2 million cases of STEMI and 5 million cases of NSTEMI. The prevalence is expected to rise throughout the forecast period.

• Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

• Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal®, Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others

• The Myocardial Infarction epidemiology based on gender analyzed that the prevalence of myocardial infarction (MI) is more common among males as compared to females

• The Myocardial Infarction market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myocardial Infarction pipeline products will significantly revolutionize the Myocardial Infarction market dynamics.

Myocardial Infarction Overview

Myocardial infarction, commonly known as a heart attack, occurs when the blood flow to a part of the heart muscle is blocked for an extended period. This blockage typically happens due to the rupture of a plaque buildup in one of the coronary arteries, which supply oxygen-rich blood to the heart muscle. Without adequate blood flow, the affected portion of the heart muscle begins to die.

Get a Free sample for the Myocardial Infarction Market Report:

https://www.delveinsight.com/report-store/myocardial-infarction-market

Myocardial Infarction Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Myocardial Infarction Epidemiology Segmentation:

The Myocardial Infarction market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Myocardial Infarction

• Prevalent Cases of Myocardial Infarction by severity

• Gender-specific Prevalence of Myocardial Infarction

• Diagnosed Cases of Episodic and Chronic Myocardial Infarction

Download the report to understand which factors are driving Myocardial Infarction epidemiology trends @ Myocardial Infarction Epidemiology Forecast

Myocardial Infarction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myocardial Infarction market or expected to get launched during the study period. The analysis covers Myocardial Infarction market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Myocardial Infarction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Myocardial Infarction Therapies and Key Companies

• JARDIANCE (empagliflozin): Boehringer Ingelheim/ Eli Lilly

• Pelacarsen: Novartis

• FARXIGA(dapagliflozin): AstraZeneca

• Dutogliptin: Recardio

• Selatogrel: Idorsia Pharmaceuticals

• abciximab: Eli Lilly and Company

• Empagliflozin: Boehringer Ingelheim

• Aliskiren: Novartis

• Eplerenone: Pfizer

• Fulacimstat (BAY1142524): Bayer

• Prochymal®: Mesoblast, Inc.

• Angiomax (bivalirudin) anticoagulant: The Medicines Company

• TNK-tPA: Boehringer Ingelheim

• MCC-135: Mitsubishi Tanabe Pharma

• ATH3G10: Athera Biotechnologies

• RO4905417: Hoffmann-La Roche

• Selatogrel: Idorsia Pharmaceuticals, and others

Discover more about therapies set to grab major Myocardial Infarction market share @ Myocardial Infarction Treatment Market

Myocardial Infarction Market Strengths

• Increasing focus on the secondary preventive measure to avoid recurrent/new events, and lifestyle changes, along with the growing number of smokers and increasing cases of obesity, diabetes, hypertension, and others, are expected to foster the market growth of Myocardial Infarction

Myocardial Infarction Market Opportunities

• Major cost drivers in the 7MM healthcare system are heart attacks and strokes. The volume of the MI market is incredibly large. The patient receives several therapies concurrently. The smallest patient share portion can provide pharmaceutical companies with options worth millions of dollars

Scope of the Myocardial Infarction Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Myocardial Infarction Companies: Novartis, AstraZeneca, Recardio, Idorsia Pharmaceuticals, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Bayer, Mesoblast, Inc., The Medicines Company, Mitsubishi Tanabe Pharma, Athera Biotechnologies, Hoffmann-La Roche, Idorsia Pharmaceuticals, and others

• Key Myocardial Infarction Therapies: JARDIANCE (empagliflozin), Pelacarsen, FARXIGA(dapagliflozin), Dutogliptin, Selatogrel, abciximab, Empagliflozin, Aliskiren, Eplerenone, Fulacimstat (BAY1142524), Prochymal®, Angiomax (bivalirudin) anticoagulant, TNK-tPA, MCC-135, ATH3G10, RO4905417, Selatogrel, and others

• Myocardial Infarction Therapeutic Assessment: Myocardial Infarction current marketed and Myocardial Infarction emerging therapies

• Myocardial Infarction Market Dynamics: Myocardial Infarction market drivers and Myocardial Infarction market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Myocardial Infarction Unmet Needs, KOL’s views, Analyst’s views, Myocardial Infarction Market Access and Reimbursement

To know more about Myocardial Infarction companies working in the treatment market, visit @ Myocardial Infarction Clinical Trials and Therapeutic Assessment

Table of Contents

1. Myocardial Infarction Market Report Introduction

2. Executive Summary for Myocardial Infarction

3. SWOT analysis of Myocardial Infarction

4. Myocardial Infarction Patient Share (%) Overview at a Glance

5. Myocardial Infarction Market Overview at a Glance

6. Myocardial Infarction Disease Background and Overview

7. Myocardial Infarction Epidemiology and Patient Population

8. Country-Specific Patient Population of Myocardial Infarction

9. Myocardial Infarction Current Treatment and Medical Practices

10. Myocardial Infarction Unmet Needs

11. Myocardial Infarction Emerging Therapies

12. Myocardial Infarction Market Outlook

13. Country-Wise Myocardial Infarction Market Analysis (2020–2034)

14. Myocardial Infarction Market Access and Reimbursement of Therapies

15. Myocardial Infarction Market Drivers

16. Myocardial Infarction Market Barriers

17. Myocardial Infarction Appendix

18. Myocardial Infarction Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myocardial Infarction Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Pfizer, Novartis, AstraZeneca, Recardio, Idorsia Pharma, Eli Lilly, Boehringer Ingelheim

“NASH market Report”

DelveInsight’s “Nonalcoholic Steatohepatitis Market Insight, Epidemiology And Market Forecast – 2034” report provides a comprehensive analysis of the NASH epidemiological trends, treatment approaches, and market dynamics across the 7MM, which include the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

The NASH market size in the 7MM was valued at approximately USD 2 billion in 2023 and is projected to experience notable growth throughout the forecast period (2024-2034). The US dominated the Nonalcoholic Steatohepatitis market in 2023, accounting for approximately USD 1.5 billion of the total market share in the studied region. Further, Germany accounted for the maximum Nonalcoholic Steatohepatitis market size among European countries, with USD 89 million in 2023.

Download the NASH Market report to understand which factors are driving the MASH therapeutic market @ NASH Market Trends.

NASH (Nonalcoholic Steatohepatitis) was officially renamed to MASH (Metabolic Dysfunction-Associated Steatohepatitis) in 2023 by leading liver disease authorities, including the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), to better reflect its metabolic origins. This change is part of a broader overhaul of fatty liver disease terminology. The updated nomenclature aims to reduce stigma, improve diagnostic clarity, and align disease names more closely with underlying metabolic risk factors, ultimately supporting better patient care and research efforts worldwide.

The report reveals that approximately 42 million prevalent NASH cases existed in the 7MM in 2023, with roughly 15 million total cases diagnosed, a number projected to increase steadily by the end of 2034. Epidemiological data further indicate that among diagnosed cases in the United States, the F1 stage of liver fibrosis comprised around 38% of patients in 2023, underscoring the significant burden of early-stage disease that may progress to more severe fibrosis without intervention.

Additionally, gender-specific analysis of NASH prevalence reveals a notable disparity, with male patients accounting for approximately 56% of total diagnosed cases across the 7MM in 2023, a trend projected to continue till 2034.

Discover evolving trends in the NASH patient pool forecasts @ NASH Epidemiology Analysis.

The report also analyzes the current and emerging trends in the nonalcoholic steatohepatitis treatment market. The NASH treatment landscape witnessed a transformative milestone with the approval of REZDIFFRA by Madrigal Pharmaceuticals (NASDAQ: MDGL) in March 2024, marking a pivotal advancement as the only FDA-approved therapy for adults with non-cirrhotic NASH accompanied by moderate to advanced liver fibrosis. The robust efficacy and safety profile demonstrated in two large Phase III MAESTRO studies positions REZDIFFRA as the foundational therapy for NASH patients.

Beyond REZDIFFRA, several emerging therapies are also poised to reshape the future of NASH treatment. In November 2024, Novo Nordisk (CPH: NOVO-B) announced promising results from Phase III trials for Semaglutide in treating nonalcoholic steatohepatitis. This glucagon-like peptide-1 receptor agonist is expected to play a significant role in addressing the metabolic dysfunctions associated with NASH.

In April 2025, 89bio (NASDAQ: ETNB) announced significant progress in the clinical development of pegozafermin, an innovative FGF21 analog for treating NASH. Currently undergoing Phase III trials, pegozafermin holds a Breakthrough Therapy designation from the FDA and PRIME status from the EMA, positioning it as a potential game-changer in addressing liver and cardiometabolic diseases. This emerging drug is expected to launch in the US NASH market by 2026, reducing the disease burden significantly.

Other emerging therapies for the NASH treatment include GLP-1/glucagon receptor agonists, such as Tirzepatide from Eli Lilly and Survodutide from Boehringer Ingelheim. Additionally, FGF21 analogues like Efruxifermin from Akero Therapeutics (NASDAQ: AKRO) and thyroid hormone receptor (THR-β) agonists, including VK2809 from Viking Therapeutics and ALG-055009 from Aligos Therapeutics, are currently undergoing clinical trials to evaluate their safety, efficacy, and tolerability in patients with NASH.

In February 2025, Galectin Therapeutics’ belapectin demonstrated a more than 68% reduction in new varices among US patients in the Phase IIb/III NAVIGATE trial. Galectin (NASDAQ: GALT) anticipates releasing 36-month follow-up data in Q2 2025, with plans to engage the FDA and potential partners on regulatory pathways. These findings position belapectin as a potential first-in-class therapy for NASH cirrhosis with portal hypertension, addressing a significant patient population in the US lacking FDA-approved treatments. These developments, alongside other pipeline advancements, signal a dynamic shift in the therapeutic approach to NASH management.

Discover recent advancements in the NASH treatment landscape @ NASH Recent Developments.

The competitive landscape for NASH therapeutics continues to evolve rapidly, with numerous pharmaceutical companies driving innovations in the NASH therapeutic area. Key players shaping the future of NASH treatment include Inventiva Pharma (EPA: IVA), Zydus Therapeutics (NSE: ZYDUSLIFE), Novo Nordisk A/S (CPH: NOVO-B), Eli Lilly and Company (NYSE: LLY), Madrigal Pharmaceuticals (NASDAQ: MDGL), Terns Inc. (NASDAQ: TERN), Intercept Pharmaceuticals (NASDAQ: ICPT), Enyo Pharma, 89bio Inc. (NASDAQ: ETNB), Akero Therapeutics Inc. (NASDAQ: AKRO), and Galectin Therapeutics (NASDAQ: GALT), among others.

The advent of REZDIFFRA and several promising pipeline developments signal a new era in NASH management. As understanding of disease pathogenesis advances and novel therapies target various cellular and molecular NASH pathways involved, patients and healthcare providers can anticipate a future with expanded treatment options, improved outcomes, and potentially reduced disease burden. The NASH market is positioned for substantial growth, driven by innovation, increasing prevalence, and the critical unmet need for effective therapeutic interventions in this progressive liver disease.

Table of Contents

1. Key Insights

2. Executive Summary of Nonalcoholic Steatohepatitis (NASH)

3. Competitive Intelligence Analysis for Nonalcoholic Steatohepatitis (NASH)

4. Nonalcoholic Steatohepatitis (NASH): Market Overview at a Glance

5. Nonalcoholic Steatohepatitis (NASH): Disease Background and Overview

6. NASH Patient Journey

7. NASH Epidemiology and Patient Population

8. Nonalcoholic Steatohepatitis Treatment Algorithm, Current Treatment, and Medical Practices

9. NASH Unmet Needs

10. Key Endpoints of NASH Treatment

11. NASH Marketed Products

12. NASH Emerging Therapies

13. Nonalcoholic Steatohepatitis (NASH): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Nonalcoholic Steatohepatitis Market Outlook

16. Access and Reimbursement Overview of Nonalcoholic Steatohepatitis (NASH)

17. KOL Views

18. NASH Market Drivers

19. NASH Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Non-Alcoholic Steatohepatitis (NASH) Pipeline Insight

Non-Alcoholic Steatohepatitis Pipeline Insight provides comprehensive insights about the NASH pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the NASH companies, including Guangdong Raynovent Biotech, Dr. Falk Pharma GmbH, Enyo Pharma, Viking Therapeutics, Eli Lilly and Company, Sagimet Biosciences, Terns, Sinew Pharma, Madrigal Pharmaceuticals, Hepion Pharmaceuticals, Poxel SA, Pfizer, CytoDyn, Altimmune, Oramed, Ltd, PharmaKing, Can-Fite Biopharma, and Cirius Therapeutics, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Nonalcoholic Steatohepatitis Market is Projected for Substantial Expansion From ~USD 2 Billion in 2023, Driven by FDA Approvals and Emerging Therapies | DelveInsight

“ESR1-Mutated Metastatic Breast Cancer Market Report”

DelveInsight’s “ESR1 Mutated Metastatic Breast Cancer – Market Insight, Epidemiology And Market Forecast – 2034” report delivers comprehensive insights into the disease landscape, historical and forecasted epidemiology, as well as ESR1 Mutated Metastatic Breast Cancer market trends across the 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan). The report reveals that the ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in 2023, is projected to experience substantial growth during the forecast period (2024-2034). Furthermore, the US accounts for the largest market share, representing approximately 63% of the total market in 2023, followed by the EU4 and the UK, which collectively capture nearly 29%. Among EU4 countries, Germany leads with the largest market share of approximately USD 90 million.

Download the ESR1 mutated metastatic breast cancer Market report to understand which factors are driving the ESR1 mutated metastatic breast cancer therapeutic market @ ESR1 mutated metastatic breast cancer Market Trends.

Rising detection rates of ESR1 mutations primarily drive this growth, approval of novel targeted therapies, and increasing focus on precision medicine approaches by key pharmaceutical players including AstraZeneca (NASDAQ: AZN), Olema Pharmaceuticals (NASDAQ: OLMA), Arvinas (NASDAQ: ARVN), Sermonix Pharmaceuticals, Roche (SWX: ROG), Eli Lilly and Company (NYSE: LLY), H3 Biomedicine, Eisai (TYO: 4523), Pfizer (NYSE: PFE), Sun Pharma Advanced Research Company (NSE: SPARC), Zenopharm, Daiichi Sankyo (TYO: 4568), and others.

The epidemiological analysis highlights the increasing prevalence of ESR1 mutations in metastatic settings, with the total diagnosed ESR1-mutated Metastatic Breast Cancer prevalent cases in the 7MM comprising approximately 44K cases in 2023. While ESR1 mutations are relatively rare in primary tumors, their prevalence significantly increases in metastatic, endocrine therapy-resistant cancers, underscoring the critical need for targeted therapeutic approaches to address this specific molecular alteration that is associated with poorer clinical outcomes and shorter progression-free survival.

Discover evolving trends in the ESR1 mutated metastatic breast cancer patient pool forecasts @ ESR1 mutated metastatic breast cancer Epidemiology Analysis.

The current treatment landscape witnessed a significant milestone with the approval of ORSERDU (elacestrant) by Stemline Therapeutics, a wholly owned subsidiary of the Menarini Group. Approved by the FDA in January 2023 and subsequently in Europe in September 2023, ORSERDU represents the first endocrine innovation in 20 years, specifically targeting ESR1 mutations in ER+, HER2-, advanced or metastatic breast cancer patients with disease progression following at least one line of endocrine therapy. This oral selective estrogen receptor degrader (SERD) has demonstrated efficacy in patients with ESR1 mutations who previously had limited treatment options.

The ESR1-mutated metastatic breast cancer pipeline is robust, with several promising candidates in late-stage development that target novel pathways and molecular mechanisms. Camizestrant (AZD9833) from AstraZeneca, an oral SERD that has shown antitumor efficacy in preclinical models, is in Phase III development with Fast Track Designation from the FDA. The SERENA-6 trial is evaluating Camizestrant in combination with CDK4/6 inhibitors (palbociclib or abemaciclib), with an anticipated filing acceptance in 2025. Another notable candidate is Lasofoxifene by Sermonix Pharmaceuticals, a selective estrogen receptor modulator (SERM) that has also received Fast Track Designation for treating women with ER+ metastatic breast cancer with ESR1 mutations.

Recent market developments include the expanding role of next-generation SERDs and SERMs as potential solutions for overcoming resistance to conventional endocrine therapies. The emergence of oral SERDs represents a significant advance over fulvestrant, which requires intramuscular administration and has pharmacokinetic limitations. These novel agents are being evaluated both as monotherapies and in combination with targeted therapies such as CDK4/6 inhibitors, presenting new opportunities for treatment sequencing and personalized medicine approaches.

In March 2025, Arvinas and Pfizer announced positive topline results from the Phase III VERITAC-2 clinical trial, which evaluated vepdegestrant, an investigational oral PROTAC estrogen receptor degrader, as monotherapy versus fulvestrant in adults whose disease had progressed following prior treatment with CDK4/6 inhibitors and endocrine therapy. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to fulvestrant, representing the first pivotal Phase III data for a PROTAC degrader in this setting and supporting the potential of vepdegestrant as a targeted therapy for patients with ESR1-mutated metastatic breast cancer.

Additionally, in April 2025, recent results from the phase III EMBER-3 trial (NCT04975308) showed that the combination of imlunestrant with abemaciclib demonstrated a median PFS of 9.4 months versus 5.5 months with imlunestrant alone. This significant improvement highlights the potential of this all-oral regimen as a promising new treatment option for patients with ESR1 mutations whose disease has progressed on prior endocrine therapy.

In January 2025, the FDA approved DATROWAY from AstraZeneca and Daiichi Sankyo for adult patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy. The studies have shown promising results in patients with various genetic alterations, including ESR1 mutations, further driving the treatment landscape.

Unlock which ESR1-mutated metastatic breast cancer emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the ESR1-mutated Metastatic Breast Cancer Drug Insights

According to DelveInsight’s analysis, the future market landscape is expected to be significantly influenced by the introduction of these novel targeted therapies, improved ESR1 mutation detection methods, and increasing incorporation of biomarker testing in clinical practice. The ESR1-mutated metastatic breast cancer market is projected to witness substantial growth as more patients are diagnosed with ESR1 mutations and as emerging therapies with improved efficacy profiles enter the market over the forecast period.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. ESR1-Mutated Metastatic Breast Cancer Market Overview at a Glance in the 7MM

7. Disease Background and Overview

8. ESR1-Mutated Metastatic Breast Cancer Epidemiology and Patient Population of the 7MM

9. ESR1-Mutated Metastatic Breast Cancer Patient Journey

10. Key Endpoints in ESR1-mutated Metastatic Breast Cancer

11. Key Cross-Competition of Drugs

12. ESR1-Mutated Metastatic Breast Cancer Marketed Drug

13. ESR1-Mutated Metastatic Breast Cancer Emerging Drugs

14. ESR1-mutated Metastatic Breast Cancer: The 7MM Market Analysis

15. ESR1-Mutated Metastatic Breast Cancer Unmet Needs

16. SWOT Analysis

17. KOL Views

18. Market Access and Reimbursement

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Related Reports:

ESR1-Mutated Metastatic Breast Cancer Pipeline Insight

ESR1-Mutated Metastatic Breast Cancer Pipeline Insight provides comprehensive insights about the ESR1-Mutated Metastatic Breast Cancer pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the ESR1-Mutated metastatic breast cancer companies, including AstraZeneca (NASDAQ: AZN), Olema Pharmaceuticals (NASDAQ: OLMA), Arvinas (NASDAQ: ARVN), Sermonix Pharmaceuticals, Roche (SWX: ROG), Eli Lilly and Company (NYSE: LLY), H3 Biomedicine, Eisai (TYO: 4523), Pfizer (NYSE: PFE), Sun Pharma Advanced Research Company (NSE: SPARC), and Zenopharm, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, Driven by FDA Approvals and a Robust Pipeline | DelveInsight

“Lung Adenocarcinoma Therapeutic Market Report”

DelveInsight’s latest report, “Lung Adenocarcinoma – Market Insight, Epidemiology And Market Forecast – 2032”, provides detailed epidemiological data along with insights into market trends, competitive landscape analysis, and assessments of the patient journey. The lung adenocarcinoma market across the 7MM is experiencing robust growth due to several contributing factors, including the rising incidence of lung cancer cases, advances in targeted therapies and immunotherapies, enhanced awareness and screening initiatives, substantial investments in research and development, and relevant environmental factors. The United States leads the market, accounting for the largest share due to its high disease prevalence, advanced healthcare infrastructure, and significant healthcare spending. Approximately 60% of all lung cancers in the US are adenocarcinomas. This trend is expected to continue throughout the forecast period.

Download the Lung Adenocarcinoma Market report to understand which factors are driving the Lung Adenocarcinoma therapeutic market @ Lung Adenocarcinoma Market Trends.

The report highlights the significant prevalence and economic impact of Lung Adenocarcinoma across the 7MM. Adenocarcinoma is the most common histological subtype of lung cancer, with distinct patterns in incidence, mortality, and risk factors. A notable trend observed is the increasing incidence among women, particularly those under 50, compared to men in the U.S. This shift is attributed to changing smoking patterns and potential hormonal influences. While most diagnoses occur in individuals aged 65 and older, the rising rates among younger women are particularly concerning, especially in the U.S. and Europe.

Discover evolving trends in the Lung Adenocarcinoma patient pool forecasts @ Lung Adenocarcinoma Epidemiology Analysis.

DelveInsight’s analysis reveals that the Lung Adenocarcinoma therapeutics market has undergone transformative changes in recent years, shifting from conventional chemotherapy approaches to precision medicine paradigms. Current treatment protocols incorporate targeted therapies addressing specific genetic alterations, including EGFR, ALK, ROS1, and BRAF mutations, which have shown superior efficacy and tolerability compared to traditional cytotoxic regimens. Immunotherapy agents targeting immune checkpoints have also revolutionized the management of this condition, particularly for patients with PD-L1 expression or high tumor mutational burden.

In December 2024, the FDA granted accelerated approval to BIZENGRI (Merus) for adult patients with advanced, unresectable, or metastatic NSCLC harboring NRG1 gene fusion, making a significant advancement in the personalized treatment landscape.

The Lung Adenocarcinoma pipeline is robust with several emerging therapies under development. Among these, two noteworthy drugs are bemcentinib and letaplimab. Bemcentinib, developed by BerGenBio (FRA: 7BG0), is an oral inhibitor that targets the AXL receptor tyrosine kinase. This kinase plays a vital role in tumor growth and treatment resistance, and bemcentinib is currently undergoing Phase II clinical trials. Letaplimab, developed by Innovent Biologics (HKG: 1801), is a monoclonal antibody that blocks the CD47 protein, which helps the immune system recognize and destroy cancer cells more effectively. Early clinical data indicate that letaplimab is well-tolerated and enhances the body’s immune response against tumors.

Recent regulatory milestones include the FDA’s breakthrough therapy designation for sacituzumab tirumotecan (Merck & Co) in December 2024, alongside a Fast Track designation for DELTACEL (Kiromic BioPharma) in August 2024. AbbVie progressed its development program by submitting a Biologics License Application for elotuzumab vedotin in September 2024. These advancements in the pipeline reflect a growing focus on the Lung Adenocarcinoma therapeutics landscape.

Discover recent advancements in the Lung Adenocarcinoma treatment landscape @ Lung Adenocarcinoma Recent Developments.

In conclusion, the future of the Lung Adenocarcinoma market appears promising. Several key factors, including rising disease incidence, technological advancements in targeted therapies, and increased awareness, are expected to shape its evolution. At the same time, challenges related to treatment affordability, disparities in healthcare access, and management of resistant disease variants will require innovative approaches. The market’s dynamic pipeline indicates a shift toward more personalized and effective therapies for Lung Adenocarcinoma. According to DelveInsight’s comprehensive analysis, this growth trajectory, along with ongoing clinical trials exploring novel mechanisms of action and combination approaches, promises to redefine patient outcomes and treatment paradigms in the coming years.

Table of Contents

1. Key Insights

2. Executive Summary of Lung Adenocarcinoma

3. Competitive Intelligence Analysis for Lung Adenocarcinoma

4. Lung Adenocarcinoma: Market Overview at a Glance

5. Lung Adenocarcinoma: Disease Background and Overview

6. Patient Journey

7. Lung Adenocarcinoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Lung Adenocarcinoma Unmet Needs

10. Key Endpoints of Lung Adenocarcinoma Treatment

11. Lung Adenocarcinoma Marketed Products

12. Lung Adenocarcinoma Emerging Therapies

13. Lung Adenocarcinoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Lung Adenocarcinoma

17. KOL Views

18. Lung Adenocarcinoma Market Drivers

19. Lung Adenocarcinoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Related Reports:

Lung Adenocarcinoma Pipeline Insight

Lung Adenocarcinoma Pipeline Insight provides comprehensive insights about the lung adenocarcinoma pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the lung adenocarcinoma companies, including BerGenBio, Innovent Biologics, Lantern Pharma Inc., Celltrion, Pionyr Immunotherapeutics Inc., Onconova Therapeutics, Inc., Pfizer, Chugai Pharmaceutical, Novartis Oncology, Alaunos Therapeutics, Tmunity Therapeutics, Imugene Limited, Hoffmann-La Roche, and Cantargia, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lung Adenocarcinoma Therapeutic Market on Track for Significant Growth by 2032 | DelveInsight